Complete Histologic Response of Regionally Metastatic Melanoma Treated with Intralesional Interleukin 2, Topical Retinoid and Imiquimod

Main Article Content

William Schaffenburg
Walter Reed National Military Medical Center 8901 Wisconsin Ave, Bethesda, MD 20889
http://orcid.org/0000-0001-6906-6890
Joshua Davis
Walter Reed National Military Medical Center Pathology Department

Nicholas Logemann
Dermatology Department, Naval Medical Center San Diego, CA

Meagan Simpson
Dermatology Department, Walter Reed National Military Medical Center, Bethesda, MD

Keywords

Melanoma, Interleukin 2

Abstract

Abstract not available.

References

1. Shi VY, Tran K, Patel F, et al. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. J Am Acad Dermatol. 2015 Oct;73(4):645-54. doi: 10.1016/j.jaad.2015.06.060. Epub 2015 Aug 7.

2. Miki Garcia M, Ono Y, Martinez S, et al. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream Melanoma Research. 21(3):235–243, JUNE 2011 DOI: 10.1097/CMR.0b013e328345e95e,
PMID: 21464773

3. Green DS, Bodman-Smith AG, Fischer MD. “Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma” BJ Derm, 2007 Feb; 156(2): 337-345. doi: https://doi.org/10.1111/j.1365-2133.2006.07664.x

4. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2010(12):180–190. https://doi.org/10.1038/nri3156

Article Sidebar

PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.6.14

Article Details

How to Cite
Schaffenburg, W., Davis, J., Logemann, N., & Simpson, M. (2020). Complete Histologic Response of Regionally Metastatic Melanoma Treated with Intralesional Interleukin 2, Topical Retinoid and Imiquimod. SKIN The Journal of Cutaneous Medicine, 4(6), 575–578. https://doi.org/10.25251/skin.4.6.14
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.